CGRP plays a complex dual role in osteoarthritis — promoting synovial inflammation while also potentially supporting cartilage regeneration, making it a challenging but promising therapeutic target.
No disease-modifying OA drugs existOsteoarthritis remains the most common age-related joint disease with zero disease-modifying treatments. CGRP's dual role in driving inflammation while supporting cartilage repair makes it a complex but potentially transformative therapeutic target.
What the researchers found
CGRP plays an important role in OA synovial inflammation, contributing to the inflammatory cascade that damages joint tissues. However, the review also identifies CGRP's physiological roles in cartilage maintenance and potential contributions to cartilage regeneration.
The dual nature of CGRP in OA — driving inflammation while potentially supporting tissue repair — creates both challenges and opportunities for therapeutic development. The authors highlight innovative strategies for targeting CGRP to enhance cartilage regeneration rather than simply blocking the peptide entirely, as is done in migraine therapy.
Why it matters
Osteoarthritis is the most common joint disease worldwide and a leading cause of disability in older adults, yet there are no disease-modifying drugs — only treatments that manage symptoms. The discovery that CGRP has both harmful (inflammatory) and helpful (regenerative) effects in joints is significant because anti-CGRP drugs already exist for migraine. Understanding these dual roles is essential before repurposing migraine drugs for OA, and could lead to entirely new therapeutic strategies based on selective CGRP modulation.
How the study worked
This is a narrative review that synthesizes current evidence on CGRP's roles in osteoarthritis-affected tissues. The authors first review the fundamental physiology and pathology of CGRP in cartilage, then summarize evidence from multiple studies on CGRP in OA, and finally examine potential therapeutic strategies for targeting CGRP to promote cartilage regeneration.
What this study cannot tell us
This is a narrative review that synthesizes existing literature without performing systematic analysis or meta-analysis. The evidence for CGRP's regenerative role in cartilage is still emerging and largely from preclinical studies. The optimal approach to CGRP modulation in OA (blocking vs. enhancing vs. targeted delivery) is theoretical and untested in clinical trials. The relationship between CGRP-mediated inflammation and cartilage damage may vary across different OA subtypes and disease stages.
How to read the evidence
This is a narrative review summarizing current understanding of CGRP in osteoarthritis without generating new data or performing systematic analysis. The evidence cited is largely from preclinical studies, and the therapeutic strategies discussed are at a conceptual stage. The review provides a valuable synthesis but represents expert opinion rather than clinical evidence.
When this study was published
Published in 2025, this review captures the current state of a rapidly developing research area at the intersection of peptide biology and rheumatology. The growing use of anti-CGRP drugs for migraine adds urgency to understanding CGRP's roles beyond headache.
The bigger picture
The success of anti-CGRP antibodies for migraine has raised questions about what happens when this peptide is blocked long-term throughout the body. CGRP is expressed in many tissues beyond the brain, including joints, bones, and blood vessels. This review highlights a potential concern: while blocking CGRP reduces migraine pain, it could theoretically impact cartilage health in joints. Conversely, it opens the intriguing possibility that targeted CGRP modulation could address OA — a disease with enormous unmet medical need. The overlap between the migraine and OA research communities is a developing area.
Questions still open
- Do patients on long-term anti-CGRP migraine therapy show any changes in joint cartilage health over time?
- Could localized CGRP delivery to arthritic joints promote cartilage repair without worsening systemic inflammation?
- Is CGRP's role in OA primarily through pain sensitization, inflammation, or direct effects on cartilage cells?
Common questions
Could the CGRP-blocking drugs used for migraines also help osteoarthritis?
Should I be worried about my joints if I take anti-CGRP migraine medication?
Read the original research
The Effects of Calcitonin Gene-Related Peptide on Cartilage in Osteoarthritis.
International journal of rheumatic diseases, 28(7), e70357
Citation
Ju, Yucan; Shen, Leyao; Huang, Qiang; Huang, Zeyu. (2025). The Effects of Calcitonin Gene-Related Peptide on Cartilage in Osteoarthritis.. International journal of rheumatic diseases, 28(7), e70357. https://doi.org/10.1111/1756-185x.70357